At a time when the technology sector is fluctuating at a high level, the pharmaceutical circuit, which had previously continued to be sluggish, has ushered in a “valuation repair.” According to Wind data, as of the end of July, a number of innovative drug ETFs had rebounded more than 20% from their low point during the year, drawing more than 10 billion yuan in total. Pharmaceutical-themed active equity funds had a maximum increase of more than 35%. Furthermore, many well-known fund managers, such as Zhu Shaoxing and Xie Zhiyu, have recently appeared intensively on the pharmaceutical stock allocation list, strengthening the market's focus on the pharmaceutical sector. Looking ahead to the future market, the agency believes that pharmaceuticals are expected to become one of the main structural lines of the market in the second half of the year, and that core directions such as innovative drugs and CXO are worth paying attention to.

At a time when the technology sector is fluctuating at a high level, the pharmaceutical circuit, which had previously continued to be sluggish, has ushered in a “valuation repair.” According to Wind data, as of the end of July, a number of innovative drug ETFs had rebounded more than 20% from their low point during the year, drawing more than 10 billion yuan in total. Pharmaceutical-themed active equity funds had a maximum increase of more than 35%. Furthermore, many well-known fund managers, such as Zhu Shaoxing and Xie Zhiyu, have recently appeared intensively on the pharmaceutical stock allocation list, strengthening the market's focus on the pharmaceutical sector. Looking ahead to the future market, the agency believes that pharmaceuticals are expected to become one of the main structural lines of the market in the second half of the year, and that core directions such as innovative drugs and CXO are worth paying attention to.